Showing 1‐28 of 464
GS Discovery® Transient Expression System
Biologics   |  Technical/Service brief
GS Discovery® Transient Expression System
With GS Discovery® you can.... Speed up therapeutic candidate selection with higher transient titers delivered in shorter tim...
/knowledge-center/biologics/brief/gs-discovery-transient-expression-system
4 min read
Micro-dosing – Powder in Capsule Technology Pathway from Development to Commercialization
Small Molecules   |  Webinar (on-demand)
Micro-dosing – Powder in Capsule Technology Pathway from Development to Commercialization
Micro-dosing can accelerate the journey of a drug product from early development through to commercialization. This webinar looks ...
/knowledge-center/smallmolecules/w/microdosing-development-to-commercialization
Solving Bispecific Antibody Heavy-Light Chain Mispairing with bYlok® Technology
Biologics   |  Webinar (on-demand)
Solving Bispecific Antibody Heavy-Light Chain Mispairing with bYlok® Technology
Lonza’s bYlok® bispecific pairing technology is an innovative solution that drives correct heavy-light chain pairing rates in IgG-...
/knowledge-center/biologics/w/solving-bispecific-antibody-bylok
Improving AAV Productivity and Packaging Efficiency for Transient and Producer Cell Lines Through Plasmid Engineering
Cell & Gene   |  Webinar (on-demand)
Improving AAV Productivity and Packaging Efficiency for Transient and Producer Cell Lines Through Plasmid Engineering
Adeno-associated virus (AAV) gene therapy has shown immense promise in treating various genetic disorders. Reducing AAV production...
/knowledge-center/cellgene/w/aav-productivity-transient-cell-lines-plasmid
How Does bYlok® Technology Work and How Can It Improve Bispecific Production?
Biologics   |  Video
How Does bYlok® Technology Work and How Can It Improve Bispecific Production?
Bispecific antibodies offer numerous potential clinical benefits, and the number of bispecifics in development continues to soar. ...
/knowledge-center/biologics/v/bylok-technology-overview
PBPK Modeling for Identifying and Mitigating Absorption Risks in Early Drug Development
Small Molecules   |  Webinar (on-demand)
PBPK Modeling for Identifying and Mitigating Absorption Risks in Early Drug Development
When coupled with in vitro measurements, PBPK modeling is effective in early development for 1) identifying absorption risks, 2) a...
/knowledge-center/smallmolecules/w/pbpk-modeling
The Early Advantage for IND Success and Beyond
Cell & Gene   |  White paper
The Early Advantage for IND Success and Beyond
Many of the decisions made during the early days of building and compiling the manufacturing information for your IND submission w...
/knowledge-center/cellgene/es/early-advantage-ind
Q&A: Why Use GS piggyBac® Transposase Technology for Expression of Your Biotherapeutics?
Biologics   |  Interview
Q&A: Why Use GS piggyBac® Transposase Technology for Expression of Your Biotherapeutics?
/knowledge-center/biologics/i/gs-piggybac-transposase-interview
Tackling Complexity: From Molecule to Formulation
Small Molecules   |  Article
Tackling Complexity: From Molecule to Formulation
Whatever proves the best option, the talented Lonza team has the skills to identify it, and then create a successful formulation f...
/knowledge-center/smallmolecules/a/tacking-molecule-complexity
3 min read
Simplify the encapsulation process of nucleic acid payloads with FDmiX technology
Biologics   |  Article
Simplify the encapsulation process of nucleic acid payloads with FDmiX technology
Enable a reliable, swift scale-up to cGMP manufacturing for mRNA encapsulation with the high-end FdmiX technology. Discover how to...
/knowledge-center/biologics/a/simplify-encapsulation-process-nucleic-acid-payloads-fdmix-technology
3 min read
Optimizing GMP Manufacturing of Lipid Nanoparticles
Biologics   |  Presentation (slides)
Optimizing GMP Manufacturing of Lipid Nanoparticles
Lonza is now offering next-generation encapsulation of nucleic acids with FDmiX. In this presentation you will find data demonstra...
/knowledge-center/biologics/pres/optimizing-gmp-manufacturing-lipid-nanoparticles
8 min read
Q&A: How to Maximise Cell Line Productivity and Efficiency
Biologics   |  Article
Q&A: How to Maximise Cell Line Productivity and Efficiency
In this interview, Dr. Tabitha Bullock, a principal group leader at Lonza, tells us about some of the key considerations in cel...
/knowledge-center/biologics/i/lic-maximize-cell-line-productivity
10 min read
Lonza Bend Capabilities
Small Molecules   |  Presentation (on-demand)
Lonza Bend Capabilities
At Lonza's facility in Bend (OR), our core capabilities include bioavailability enhancement, respiratory delivery, and multipartic...
/knowledge-center/smallmolecules/pres/lonza-bend-capabilities
Oral Multiparticulate Technologies
Small Molecules   |  Technical/Service brief
Oral Multiparticulate Technologies
Multiparticulates offer a number of advantages, including optimized GI tract distribution, predictable gastrointestinal (GI) trans...
/knowledge-center/smallmolecules/brief/oral-multiparticulate-technologies
6 min read
Extracellular Vesicles: Engineering New Therapeutic Delivery Modalities
Cell & Gene   |  Poster
Extracellular Vesicles: Engineering New Therapeutic Delivery Modalities
Extracellular Vesicles (EVs), including exosomes, are emerging as promising natural nano-scale platforms for delivering nucleic ac...
/knowledge-center/cellgene/post/extracellular-vesicles-engineering
Plasmid Engineering to Improve AAV Productivity and Packaging Efficiency
Cell & Gene   |  Poster
Plasmid Engineering to Improve AAV Productivity and Packaging Efficiency
The packaging efficiency (full to total capsid ratio, or F/T ratio) for Adeno-Associated Virus (AAV) is a critical quality attribu...
/knowledge-center/cellgene/post/plasmid-engineering-to-improve-aav-productivity
Can Elimination of Preclinical Animal Testing Accelerate the Path to IND?
Biologics   |  R&D Blog post
Can Elimination of Preclinical Animal Testing Accelerate the Path to IND?
The US Food and Drug Administration (FDA) can now approve Investigational New Drug (IND) applications for companies seeking to adv...
/knowledge-center/Blogs/elimination-preclinical-animal-testing
3 min read
Moving Away from Animal Testing: What are the Drivers and Which Drug Candidates Might Benefit?
Biologics   |  R&D Blog post
Moving Away from Animal Testing: What are the Drivers and Which Drug Candidates Might Benefit?
The US Food and Drug Administration (FDA) can now approve Investigational New Drug (IND) applications for companies seeking to adv...
/knowledge-center/Blogs/moving-away-from-animal-testing
4 min read
Bioavailability Enhancement Technologies
Small Molecules   |  Technical/Service brief
Bioavailability Enhancement Technologies
The increasing fraction of low-solubility compounds in drug discovery has necessitated routine use of enabling technologies to imp...
/knowledge-center/smallmolecules/brief/bioavailability-enhancement-technologies
5 min read
From Technology Selection to Final Drug Product: Material Sparing Approaches for ASD Development
Small Molecules   |  Webinar (on-demand)
From Technology Selection to Final Drug Product: Material Sparing Approaches for ASD Development
Low-solubility and poorly bioavailable compounds pose persistent challenges in pharmaceutical pipelines. This webinar delves ...
/knowledge-center/smallmolecules/w/material-sparing-approaches-asd-development
Micro-Dosing and Powder-in-Capsule Evaluations
Small Molecules   |  Technical/Service brief
Micro-Dosing and Powder-in-Capsule Evaluations
Lonza's leadership in powder-in-capsule (PIC) development using our Xcelodose™; precision powder micro-dosing systems technology s...
/knowledge-center/smallmolecules/brief/micro-dosing-and-pic-evaluations
3 min read
A Comprehensive and Flexible Approach to CMC for Fab and Fc-Fusion Development Programs
Biologics   |  White paper
A Comprehensive and Flexible Approach to CMC for Fab and Fc-Fusion Development Programs
New molecular formats are gaining momentum in today’s market. They are extremely diverse and can often encompass multiple chains a...
/knowledge-center/biologics/es/cmc-for-fab-and-fc-fusion
20 min read
Exploring Proteoforms of the IgG2 Monoclonal Antibody Panitumumab Using Microchip Capillary Electrophoresis-Mass Spectrometry
Biologics   |  Peer-reviewed publication
Exploring Proteoforms of the IgG2 Monoclonal Antibody Panitumumab Using Microchip Capillary Electrophoresis-Mass Spectrometry
The IgG2 type monoclonal antibody panitumumab is an anti-epidermal growth factor receptor (EGFR) drug used for the treatment of EG...
/knowledge-center/biologics/pub/monoclonal-antibody-panitumumab
15 min read
Automated Raman Feedback Control of Multiple Supplemental Feeds to Enable an Intensified High Inoculation Density Fed-Batch Platform Process
Biologics   |  Peer-reviewed publication
Automated Raman Feedback Control of Multiple Supplemental Feeds to Enable an Intensified High Inoculation Density Fed-Batch Platform Process
Biologics manufacturing is increasingly moving toward intensified processes that require novel control strategies in order to achi...
/knowledge-center/biologics/pub/automated-raman-feed-back
35 min read
Adaptive Bioprocessing: Utilising Inline Raman Spectroscopy for Automated Control
Biologics   |  Article
Adaptive Bioprocessing: Utilising Inline Raman Spectroscopy for Automated Control
Substantial progress has been made over the last decade in developing Raman concentration models which generalize well across cell...
/knowledge-center/biologics/a/adaptiv-bioprocessing
6 min read
Integrated API Services at Lonza Nansha
Small Molecules   |  White paper
Integrated API Services at Lonza Nansha
Lonza is constantly expanding its site in Nansha, China. It is now a premier example of a global manufacturing facility that offer...
/knowledge-center/smallmolecules/es/integrated-api-services
8 min read
Particle-Size Engineering Through Micronization
Small Molecules   |  Technical/Service brief
Particle-Size Engineering Through Micronization
Stability, flowability, dissolution rate, and bioavailability (BA) are all critical performance parameters affected by particle-si...
/knowledge-center/smallmolecules/brief/particle-size-engineering-through-micronization
5 min read
An Automated High Inoculation Density Fed-Batch Bioreactor Enabled Through N-1 Perfusion Accommodates Clonal Diversity and Doubles Titers
Biologics   |  Peer-reviewed publication
An Automated High Inoculation Density Fed-Batch Bioreactor Enabled Through N-1 Perfusion Accommodates Clonal Diversity and Doubles Titers
An important consideration for biopharmaceutical processes is the cost of goods (CoGs) of biotherapeutics manufacturing. CoGs can ...
/knowledge-center/biologics/pub/automated-fed-batch-bioreactor
20 min read
1 2 3 4 ... 17 >
Meet our experts

Our community is composed of technical experts who have decades of experience in a range of topics and project challenges.

View all experts
Meet our Biologics experts
Meet our Small Molecules experts